At present, the company has nine laboratories and a laboratory management center, including molecular biology and monoclonal technology, genetic engineering of protein genomics, bacterial polysaccharides, molecular viruses, plasma proteins and their preparations. Leading figures at home and abroad lead thousands of scientific and technological personnel and research teams to develop new products. Completed dozens of national scientific research tasks. More than one scientific research achievement 100 has been obtained, of which more than 30 have won the state science and technology commission, the Ministry of Health or the Shanghai Science and Technology Progress Award.
2. Beijing Institute of Biological Products
Beijing Institute of Biological Products, founded in 19 19, is the first specialized institution in China's history to research and produce national health and epidemic prevention and serum vaccines, and has successively developed and produced 15 kinds of products, such as the earliest vaccinia, cholera, typhoid, rabies vaccine and diphtheria antitoxin in China. The first penicillin strain in China was isolated, which achieved a breakthrough in biological products in China.
20 16 On August 23rd, the kick-off meeting of phase I clinical trial of tetravalent recombinant HPV vaccine was held in Chaoyang District Center for Disease Control and Prevention, Beijing. The tetravalent recombinant HPV vaccine in this clinical trial was jointly declared by Sinopharm Zhongsheng Research Institute (Beijing Company) and Chengdu Company, and the clinical research and industrialization of the vaccine were completed.
3. Wuhan Bowo Biotechnology Co., Ltd.
Wuhan Bowo Biotechnology Co., Ltd. was established on 20 12. It is a national high-tech enterprise specializing in the research, development, manufacture and marketing of high-end vaccines for human use, and has obtained qualifications or honors such as Hubei New Vaccine and Recombinant Protein Engineering Laboratory, Hubei Enterprise Technology Center, Hubei Biosafety Laboratory and Wuhan Gazelle Enterprise.
Is a member of the vaccine enterprise alliance of developing countries. The company is committed to the research and development and industrialization of human multivalent rotavirus vaccine, new pneumococcal conjugate vaccine and other heavyweight products, and strives to provide safe, effective and high-quality vaccine products for China and the world.
4. Shanghai Zerun Biotechnology Co., Ltd..
Shanghai Zerun Biotechnology Co., Ltd. was established in 2003, located in Zhangjiang Hi-tech Park, Pudong New Area, Shanghai. Focus on the research and development and industrialization of new products of recombinant human vaccines, and undertake major national new drug creation projects and national high-tech enterprises. At the end of 20 12, Zerun Bio successfully completed the integration with watson biological Science and Technology Co., Ltd., a company listed on Shenzhen Growth Enterprise Market, and became its holding subsidiary.
Zerun Bio's R&D project has been continuously supported by special funds from the state and local governments, including a number of national "Eleventh Five-Year Plan" major new drug creation projects and Shanghai scientific research projects. At the same time, Zerun Bio attaches great importance to the protection of intellectual property rights and protects the core technologies of scientific research projects. Up to now, dozens of invention patents have been applied and authorized at home and abroad.
Using the new recombination vaccines R&D platform, Zerun Bio is developing a series of new recombination vaccines products, including bivalent human papillomavirus (HPV) vaccine that has entered the third phase of clinical practice, nine-valent human papillomavirus (HPV) vaccine that has been declared for clinical practice and other recombination vaccines varieties that have good market prospects and are in the preclinical research stage;
5. Chengdu Institute of Biological Products
Chengdu Institute of Biological Products is one of the largest research and production bases of biological products in China, and it belongs to China Biotechnology Group, an important state-owned backbone enterprise managed by SASAC in the State Council. Since the establishment of 1958, Chengdu, a national medicine company, has been committed to the research of medical microbiology, immunology, cell engineering and genetic engineering for a long time as the planned immunization cooperation center of six provinces, municipalities and autonomous regions in southwest China.
Production and management of various biological products such as preventive products, blood products, diagnostic products and genetic engineering products. The company has been awarded the titles of Sichuan State-owned Assets Supervision and Administration Commission, Sichuan Top 20 Pharmaceutical Manufacturing Enterprises and Chengdu 100 Top Enterprises for many years, and has been awarded the titles of advanced enterprises in quality management and honesty and law-abiding.
The industrialization project of "Recombinant Human Papillomavirus Vaccine" of Chengdu Institute of Biological Products Co., Ltd., as one of the nine key projects under construction in Sichuan pharmaceutical industry in 20 17, started in August of 20 17.